Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward

Gastrointestinal stromal tumor (GIST) represents a paradigm for clinically effective targeted inhibition of oncogenic driver mutations in cancer. Five drugs are currently positioned as the standard of care for the treatment of advanced or metastatic GIST patients. This is the result of continuous, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lostes-Bardaji, M. Julia, García-Illescas, David, Valverde, Claudia, Serrano, César
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797597/
https://www.ncbi.nlm.nih.gov/pubmed/33473249
http://dx.doi.org/10.1177/1758835920986498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797597/
https://www.ncbi.nlm.nih.gov/pubmed/33473249
http://dx.doi.org/10.1177/1758835920986498

Ejemplares similares